<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pneumococcal vaccination in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pneumococcal vaccination in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pneumococcal vaccination in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elaine I Tuomanen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Inci Yildirim, MD, PhD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Streptococcus pneumoniae </em>(pneumococcus) is a leading cause of serious illnesses in children.</p><p>Pneumococcal vaccination for healthy children and children at increased risk of invasive pneumococcal disease will be reviewed here. Pneumococcal vaccination in adults, the microbiology and pathogenesis of pneumococcal disease, and pneumococcal pneumonia in children are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7023.html" rel="external">"<i>Streptococcus pneumoniae</i>: Microbiology and pathogenesis of infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6060.html" rel="external">"Pneumococcal pneumonia in children"</a>.)</p><p></p><p class="headingAnchor" id="H1629588217"><span class="h1">PNEUMOCOCCAL VACCINES</span><span class="headingEndMark"> — </span>The surface capsular polysaccharide of <em>S. pneumoniae</em> determines the serotype and provokes a type-specific protective immune response [<a href="#rid1">1</a>]. More than 102 pneumococcal serotypes have been identified so far. It is not possible to include all serotypes in a pneumococcal vaccine; the serotypes most frequently isolated from patients with invasive disease are included in the available vaccines. (See  <a class="medical medical_review" href="/z/d/html/7023.html" rel="external">"<i>Streptococcus pneumoniae</i>: Microbiology and pathogenesis of infection", section on 'Capsule'</a>.)</p><p class="headingAnchor" id="H2932233970"><span class="h2">Conjugate vaccines</span><span class="headingEndMark"> — </span>Pneumococcal polysaccharide-conjugate vaccines (usually called pneumococcal conjugate vaccines [PCVs]) are inactivated vaccines that consist of type-specific pneumococcal polysaccharides conjugated to a carrier protein or proteins. The carrier protein elicits a T cell-dependent memory response during the first two years of life, which increases the effectiveness of the vaccine  (<a class="graphic graphic_table graphicRef71746" href="/z/d/graphic/71746.html" rel="external">table 1</a>).</p><p>PCVs that include 7, 10, 13, 15, and 20 serotypes have been developed  (<a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">table 2</a>). The 7-valent vaccine (PCV7) is no longer available.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>10-valent vaccine</strong> – The 10-valent PCV (<a class="drug drug_pediatric" data-topicid="126388" href="/z/d/drug information/126388.html" rel="external">PCV10</a>) contains polysaccharides from 10 pneumococcal serotypes  (<a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">table 2</a>) conjugated to protein D, tetanus and diphtheria toxoids, and an aluminum adjuvant. PCV10 is not licensed in the United States but is used in other countries [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>13-valent vaccine, 15-valent vaccine, and 20-valent vaccine</strong> – If neither the 15-valent (<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>) nor the 20-valent pneumococcal conjugate vaccines (<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>) are available, the <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">13-valent pneumococcal conjugate vaccine</a> (PCV13) may be used. All three vaccines contain polysaccharides from the specified pneumococcal serotypes  (<a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">table 2</a>) conjugated to CRM197 (a nontoxic mutant of diphtheria toxin) and an aluminum adjuvant. None contain thimerosal  (<a class="graphic graphic_table graphicRef71746" href="/z/d/graphic/71746.html" rel="external">table 1</a>) [<a href="#rid3">3-5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>13-valent vaccine </strong>– <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a> is licensed to prevent invasive pneumococcal disease (IPD) caused by the 13 vaccine serotypes in children 6 weeks through 17 years of age and to prevent acute otitis media by the seven serotypes in PCV7  (<a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">table 2</a>) in children age 6 weeks through 5 years [<a href="#rid4">4</a>]. PCV13 replaced PCV7 in the routine childhood immunization schedule in the United States in 2010 [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>15-valent vaccine </strong>– <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> contains the 13 serotypes included in <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a> plus serotypes 22F and 33F. It is licensed to prevent IPD in individuals ≥6 weeks of age [<a href="#rid7">7,8</a>]. It was licensed for children &lt;18 years of age based on randomized trials that demonstrated safety and immunogenicity similar to those with PCV13 for the shared serotypes [<a href="#rid9">9-14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>20-valent vaccine </strong>–<strong> </strong><a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> contains the 15 serotypes included in <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> plus serotypes 8, 10A, 11A, 12F, and 15B. It is licensed to prevent pneumonia and IPD in children 6 weeks through 17 years of age [<a href="#rid7">7,15</a>]. In a randomized trial comparing PCV20 and <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a> in 460 infants, PCV20 was immunogenic and had a safety profile similar to PCV13 [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H1618104027"><span class="h2">Polysaccharide vaccine</span><span class="headingEndMark"> — </span>The 23-valent <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">pneumococcal polysaccharide vaccine</a> (PPSV23) is an inactivated vaccine that contains purified capsular polysaccharide antigens of 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)  (<a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">table 2</a>). The 23 serotypes were chosen to represent 85 to 90 percent of the serotypes that cause IPD in the United States. PPSV23 does not contain thimerosal  (<a class="graphic graphic_table graphicRef71746" href="/z/d/graphic/71746.html" rel="external">table 1</a>) [<a href="#rid17">17</a>].</p><p><a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> is licensed for use in people ≥2 years of age. Polysaccharide vaccines are poorly immunogenic in children younger than two years of age [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/z/d/html/3929.html" rel="external">"Assessing antibody function as part of an immunologic evaluation", section on 'Children under two years of age'</a>.)</p><p class="headingAnchor" id="H474797371"><span class="h1">ROUTINE IMMUNIZATION FOR CHILDREN &lt;5 YEARS</span><span class="headingEndMark"> — </span>Children &lt;5 years of age, particularly those &lt;2 years of age, are at increased risk for invasive pneumococcal disease (IPD), such as meningitis and bacteremia. Routine immunization with a pneumococcal conjugate vaccine (PCV) is effective in preventing IPD in vaccinated children and providing community ("herd") immunity for people who are not vaccinated. (See <a class="local">'Efficacy and effectiveness'</a> below.)</p><p>The United States Advisory Committee on Immunization Practices and the World Health Organization (WHO) recommend immunization with PCV for all infants [<a href="#rid6">6,8,20</a>].</p><p class="headingAnchor" id="H3388978336"><span class="h2">Schedule and catch-up schedule</span></p><p class="headingAnchor" id="H1404264673"><span class="h3">In the United States</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine schedule</strong> – In the United States, the routine schedule for PCV (either 15-valent PCV [<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>] or 20-valent PCV [<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>]) for all children includes a three-dose primary series and a booster dose [<a href="#rid21">21</a>]. We prefer to administer PCV20 when available. The recommended schedule is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age two months (the minimum age for this dose is 6 weeks)</p><p class="bulletIndent2"><span class="glyph">•</span>Age four months and ≥4 weeks after the first dose</p><p class="bulletIndent2"><span class="glyph">•</span>Age six months and ≥4 weeks after the second dose</p><p class="bulletIndent2"><span class="glyph">•</span>Booster dose at age 12 through 15 months and ≥8 weeks after the third dose</p><p></p><p class="bulletIndent1">If the child has only received <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>, the series may be completed with <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>. Restarting the series is not necessary.</p><p></p><p class="bulletIndent1">In preterm infants, PCV is administered according to chronologic age [<a href="#rid6">6,22-25</a>].</p><p></p><p class="bulletIndent1">Administration of PCV is discussed below. (See <a class="local">'Administration of PCV13/PCV15/PCV20 and PPSV23'</a> below.)</p><p></p><p class="bulletIndent1">The booster dose at ≥12 months is recommended to prevent breakthrough disease due to waning immunity [<a href="#rid26">26,27</a>]. In an observational study from Australia, which used a schedule consisting of three doses at age 2, 4, and 6 months without a booster dose, vaccine effectiveness declined with time since the third dose, particularly beyond 24 months [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catch-up schedule</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Healthy children between 2 and &lt;5 years of age who are incompletely immunized with PCV should receive a single dose of either <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>. We prefer PCV20 when available. The dose should be administered at least eight weeks after the most recent PCV dose (if applicable) [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent2">The Centers for Disease Control and Prevention has developed a web-based tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww2a.cdc.gov%2Fvaccines%2Fm%2Fpneumo%2Fpneumo.html&amp;token=N8qVJSrBCrbuXuD7GKvcN%2BGkwQLQ7IKRD0WskUEB1oAU%2F3x%2FQKivGUThAjjVztADglJJfWzbGBaZOZmHWPdaEw%3D%3D&amp;TOPIC_ID=6053" target="_blank">PneumoRecs VaxAdvisor</a>) to help clinicians determine which pneumococcal vaccines children need.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants and children &lt;6 years of age with certain underlying conditions who are incompletely immunized with PCV are discussed below. (See <a class="local">'Age 2 through 18 years'</a> below.)</p><p></p><p class="headingAnchor" id="H3843484289"><span class="h3">In other countries</span><span class="headingEndMark"> — </span>The WHO recommends that PCV be included in childhood immunization programs worldwide [<a href="#rid20">20</a>]. The WHO suggests that PCV be administered, beginning as early as six weeks of age, either as:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two primary doses, separated by ≥8 weeks, and a booster at age 9 to 18 months of age (2p+1 schedule), or as</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three primary doses, separated by ≥4 weeks, without a booster (3p+0 schedule)</p><p></p><p>A 2017 systematic review of randomized and observational studies concluded that both schedules are immunogenic and highly effective in preventing IPD caused by vaccine serotypes [<a href="#rid29">29</a>]. The optimal schedule may vary geographically with the epidemiology of IPD (eg, age-specific incidence and community immunity) [<a href="#rid30">30-34</a>]. The 2p+1 schedule induces higher antibody levels in the second year of life, which may help to maintain community immunity [<a href="#rid35">35</a>].</p><p>The recommended schedules for individual countries in Europe are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaccine-schedule.ecdc.europa.eu%2F&amp;token=hAC5nrgJRAh83rPs4U2YNoCvbRcaKCDdFzcO5xBYnRCBx4Y4AiuicnfZL3B%2BmfLV&amp;TOPIC_ID=6053" target="_blank">European Centre for Disease Prevention and Control</a>.</p><p class="headingAnchor" id="H3436619095"><span class="h2">Efficacy and effectiveness</span></p><p class="headingAnchor" id="H2637445025"><span class="h3">Invasive disease</span><span class="headingEndMark"> — </span>IPD is usually defined by the isolation of pneumococcus from a normally sterile body fluid (eg blood, cerebrospinal fluid). Pneumococcal pneumonia is considered to be invasive if it is complicated by empyema or associated with bacteremia.</p><p>Routine immunization of young children with PCV is effective in preventing IPD in vaccinated children. The decline is greatest for vaccine serotypes and cross-reactive serotypes (ie, nonvaccine serotypes [eg, 6A, 9N, 18B, 23A] related to vaccine serotypes [eg, 6C, 9V, 18C, 23F]) [<a href="#rid36">36,37</a>].</p><p>In a meta-analysis of six randomized trials (including more than 113,000 children) of various valencies of PCV from several countries, PCV efficacy for preventing vaccine-type IPD in children &lt;2 years of age was 80 percent (95% CI 58-90 percent) [<a href="#rid36">36</a>]. The efficacy for preventing IPD caused by all serotypes was 58 percent (95% CI 29-75 percent). Findings were similar in children with and without human immunodeficiency virus (HIV).</p><p>The effectiveness of PCV in preventing IPD in children &lt;5 years of age is confirmed by surveillance demonstrating dramatic declines in the incidence of IPD after routine infant immunization was introduced [<a href="#rid38">38-50</a>]. In the United States between 1998 and 2019, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fpneumococcal%2Fsurveillance.html&amp;token=d16IHyNTLOkxHZEFJDs%2Bcint6X09IvMBdWEN5mD%2B6LzB8tHQpJrMT%2Bj2iFJH94X1CWfzhF7lqY0vHr%2BPiMv8Rg%3D%3D&amp;TOPIC_ID=6053" target="_blank">overall incidence of IPD in children &lt;5 years</a> of age declined from 95 to 7 cases per 100,000 children, and the incidence of IPD caused by <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a> serotypes declined from 88 to 2 cases per 100,000 children [<a href="#rid38">38</a>].</p><p>After the switch from 7-valent PCV (PCV7) to <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a> (in 2010), the overall incidence of IPD continued to decline [<a href="#rid47">47,51-54</a>], although the proportion of IPD cases caused by nonvaccine serotypes increased [<a href="#rid55">55-59</a>]. In multistate surveillance in the United States during 2018 to 2019, among children &lt;5 years of age, the incidence of IPD was 7.2 per 100,000 children, PCV13 serotypes accounted for 21 percent of IPD cases, and serotypes 22F and 33F (the two additional serotypes in <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>) accounted for 15 percent of IPD cases [<a href="#rid8">8,60</a>]. Among children age 5 to 18 years, the incidence of IPD was 1.5 per 100,000, PCV13 serotypes accounted for 34 percent of IPD cases, and serotypes 22F and 33F accounted for 23 percent of IPD cases. A study of 30 high-income countries found a similar proportion of IPD cases due to serotypes 22F and 33F; in addition, the five serotypes found only in <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> accounted for 27.5 percent of IPD cases [<a href="#rid61">61</a>].</p><p>The prevalence of serious IPD due to nonvaccine serotypes highlights the importance of continued vigilance and surveillance for IPD, even in immunized children. Although the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fabcs%2Freports-findings%2Fsurvreports%2Fspneu-types.html&amp;token=48twScXHVZ2Ok4KK4CP%2Fg6D9gv2gWf74Qt24mOErRlhMbZkDaGD2OJY6mCLKRyHrhwrq6OUHlI8kepPTEZZMHfV5d70NbyP31ZdWptSH9jU%3D&amp;TOPIC_ID=6053" target="_blank">incidence of IPD and pneumococcal mortality</a> declined after the introduction of PCVs in the United States and other countries, the burden of pneumococcal disease remains substantial [<a href="#rid62">62-64</a>].</p><p>Routine immunization of infants with PCV is also effective in providing community ("herd") immunity (ie, protection for unvaccinated people, including infants and older adults) [<a href="#rid53">53,65-70</a>].</p><p class="headingAnchor" id="H2828700534"><span class="h3">Pneumonia and empyema</span><span class="headingEndMark"> — </span>PCV is modestly protective against pneumococcal pneumonia caused by vaccine serotypes as well as overall community-acquired pneumonia [<a href="#rid36">36,71-78</a>], which is often caused by pathogens other than pneumococcus, including viruses [<a href="#rid79">79</a>]. <em>S. pneumoniae</em> appears to contribute to the pathogenesis of CAP caused by other bacteria and viruses; therefore, vaccination against pneumococci may have the potential to reduce all-cause pneumonia burden [<a href="#rid74">74,80,81</a>].</p><p>In a meta-analysis of six randomized trials, PCV efficacy for preventing WHO radiographically defined pneumonia in children &lt;2 years of age was 27 percent (95% CI 15-36 percent) and for preventing clinical pneumonia was 6 percent (95% CI 2-9 percent) [<a href="#rid36">36</a>]. Findings were similar in children with and without HIV.</p><p>After the switch from PCV7 to <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a> in 2010, hospitalizations among children for culture-proven pneumococcal pneumonia (all serotypes) and complicated pneumonia declined at the eight children's hospitals in the Pediatric Multicenter Pneumococcal Surveillance Study Group [<a href="#rid71">71</a>]. Nonetheless, PCV13 serotypes 3 and 19A accounted for approximately one-half of cases between 2011 and 2014. Among 119 children hospitalized with invasive pneumococcal pneumonia at one of the eight children's hospitals between 2014 and 2017, PCV-13 serotypes were isolated from 42 percent [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H2335255269"><span class="h3">Otitis media and conjunctivitis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute otitis media</strong> – Administration of PCV is associated with a modest reduction in the incidence of acute otitis media (AOM) in infants [<a href="#rid37">37,82,83</a>]. Administration of PCV changes the nasopharyngeal flora, reducing episodes of AOM caused by pneumococcal vaccine serotypes and cross-reactive serotypes, and increasing episodes of AOM caused by other serotypes.</p><p></p><p class="bulletIndent1">The effectiveness of PCV in preventing recurrent episodes of AOM is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence", section on 'Pneumococcal conjugate vaccine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conjunctivitis</strong> – Limited evidence from population-based surveillance suggests that administration of PCV is associated with decreased rates of pneumococcal conjunctivitis, nontypeable <em>Haemophilus influenzae</em> conjunctivitis, and culture-positive conjunctivitis in children &lt;2 years of age [<a href="#rid84">84</a>].</p><p></p><p class="headingAnchor" id="H4292599062"><span class="h3">Incomplete schedules</span><span class="headingEndMark"> — </span>Children may receive fewer than the recommended number of doses of PCV if immunizations are delayed or the vaccine is not available. In observational studies, the effectiveness of incomplete schedules varied with the number and timing of doses [<a href="#rid85">85,86</a>]. Nonetheless, various combinations of three or four doses before 16 months that included at least one dose at ≥12 months provided approximately 90 percent protection against IPD due to any serotype and up to 100 percent protection against IPD due to vaccine serotypes, highlighting the importance of the booster dose. (See <a class="local">'In the United States'</a> above.)</p><p class="headingAnchor" id="H800809043"><span class="h2">Immunogenicity</span><span class="headingEndMark"> — </span>Immunogenicity is a surrogate for protection from disease. The concentrations of immunoglobulin G capsular antibodies that correlate with protection against pneumococcal disease have not been clearly defined but are proposed to be ≥0.35 mcg/mL one month after primary immunization as measured by enzyme-linked immunosorbent assay, based on a pooled meta-analysis [<a href="#rid87">87</a>]. This is the minimum protective concentration recommended by the WHO for assessing the efficacy of PCVs in infants [<a href="#rid88">88</a>].</p><p>In randomized trials, <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a> provided comparable immunogenicity to PCV7 for the serotypes included in both vaccines; in most circumstances, the new serotypes met the WHO-proposed minimum protective concentration [<a href="#rid89">89-92</a>]. Similarly, in randomized trials in healthy children and children with sickle cell disease or HIV, <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> provided comparable immunity to PCV13 [<a href="#rid9">9-14,93</a>].</p><p>Serotype-specific antibody response may be decreased by elevated levels of maternal antibody and nasopharyngeal carriage of <em>S. pneumoniae</em> before immunization [<a href="#rid94">94-97</a>]. The booster response for individual serotypes varies with the immunization schedule; reduced dose schedules may not achieve protective antibody levels for all serotypes [<a href="#rid98">98,99</a>]. The clinical significance of these observations is uncertain [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H1271588764"><span class="h1">IMMUNIZATION OF HIGH-RISK CHILDREN AND ADOLESCENTS</span></p><p class="headingAnchor" id="H851832677"><span class="h2">Target high-risk groups</span><span class="headingEndMark"> — </span>The risk of invasive pneumococcal disease (IPD) is increased in the following groups  (<a class="graphic graphic_table graphicRef68655" href="/z/d/graphic/68655.html" rel="external">table 3</a>), and these children should receive at least one dose of the <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">20-valent pneumococcal conjugate vaccine</a> (PCV20) or the 23-valent <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">pneumococcal polysaccharide vaccine</a> (PPSV23) as reviewed by age below [<a href="#rid21">21,100-106</a>]. (See <a class="local">'Aged-based immunization recommendations'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised children and adolescents, including those with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Functional or anatomic asplenia (eg, sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia or splenic dysfunction); although celiac disease has been associated with hyposplenism and an increased risk of IPD [<a href="#rid107">107</a>], the United States Advisory Committee on Immunization Practices (ACIP) does not consider it a high-risk condition [<a href="#rid6">6,100</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congenital or acquired immunodeficiency (B or T cell deficiency, complement deficiency [particularly C1, C2, C3, and C4 deficiency], phagocyte disorders [except chronic granulomatous disease])</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HIV infection [<a href="#rid108">108</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nephrotic syndrome or on maintenance dialysis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Generalized malignancy (eg, metastatic disease, disease treated with chemotherapy or radiation therapy)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hematologic malignancy (eg, leukemia, lymphoma, Hodgkin disease, multiple myeloma)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Iatrogenic immunosuppression (eg, solid organ transplant, long-term systemic glucocorticoids, tumor necrosis factor-alpha inhibitors [eg, <a class="drug drug_pediatric" data-topicid="13284" href="/z/d/drug information/13284.html" rel="external">etanercept</a>, <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a>], radiation therapy)</p><p></p><p class="bulletIndent1">Pneumococcal immunization of patients after hematopoietic cell transplantation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients", section on 'Pneumococcus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune-competent children and adolescents with anatomic barrier defects, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cerebrospinal fluid (CSF) leak</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cochlear implant (or candidate for cochlear implant) [<a href="#rid109">109</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune-competent children and adolescents with chronic medical condition (CMC):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic heart disease, particularly cyanotic congenital heart disease, cardiac failure, and cardiomyopathy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic lung disease (including moderate or severe persistent asthma) [<a href="#rid102">102</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diabetes mellitus</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic liver disease</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease (excluding children with nephrotic syndrome and/or dialysis dependence) </p><p></p><p>Although the ACIP does not include severe IPD (eg, pneumococcal meningitis with sequelae, pneumococcal pneumonia with empyema or other complication) or recurrent acute otitis media (AOM) as high-risk conditions, some experts suggest that children with a history of severe IPD or recurrent AOM receive a dose of <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> or <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> vaccine after completion of the standard recommended vaccine schedule, unless they have already received a dose of PCV20. (See <a class="local">'Invasive pneumococcal disease'</a> below and  <a class="medical medical_review" href="/z/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence", section on 'Vaccines'</a>.)</p><p class="headingAnchor" id="H3770789752"><span class="h2">Aged-based immunization recommendations</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> and <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> provide protection against serotypes that are not included in the 13-valent (<a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>) or the <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">15-valent pneumococcal conjugate vaccine</a> (PCV15)  (<a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">table 2</a>), and therefore high-risk children should receive one of these vaccines.</p><p>The Centers for Disease Control and Prevention has developed a tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww2a.cdc.gov%2Fvaccines%2Fm%2Fpneumo%2Fpneumo.html&amp;token=N8qVJSrBCrbuXuD7GKvcN%2BGkwQLQ7IKRD0WskUEB1oAU%2F3x%2FQKivGUThAjjVztADglJJfWzbGBaZOZmHWPdaEw%3D%3D&amp;TOPIC_ID=6053" target="_blank">PneumoRecs VaxAdvisor</a>) to provide customized recommendations for pneumococcal vaccination in children with underlying medical conditions.</p><p class="headingAnchor" id="H1571076229"><span class="h3">Age &lt;2 years</span><span class="headingEndMark"> — </span>Administer PCV according to the schedule for healthy children. (See <a class="local">'Schedule and catch-up schedule'</a> above.)</p><p class="headingAnchor" id="H4009464014"><span class="h3">Age 2 through 18 years</span><span class="headingEndMark"> — </span>The pneumococcal vaccination schedule for children at high risk of IPD who are age 2 through 18 years is determined by the high-risk condition and history of immunization with <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>/<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>/<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> (doses of PCV7 are not counted) and <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a>, as described below  (<a class="graphic graphic_algorithm graphicRef119302" href="/z/d/graphic/119302.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef119305" href="/z/d/graphic/119305.html" rel="external">algorithm 2</a>) [<a href="#rid6">6,100</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catch-up for children ages 2 years to &lt;6 years</strong>– Children &lt;6 years of age who have not received the full recommended PCV series (with <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>, <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>, or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>) require additional pneumococcal vaccination at this age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the child received all three doses of the primary PCV series before age 1 year but did not receive the booster dose, then administer one additional dose of <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> at least eight weeks after the most recent PCV dose. We prefer PCV20 when available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the child has any other incomplete PCV vaccination status (including no prior doses or incomplete primary series), then administer two doses of <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>. We prefer PCV20 when available. The first dose should be at least eight weeks after any previous PCV dose, and the second dose should be at least eight weeks after the first.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional doses for children who completed the recommended PCV series before age 6 years </strong>– For children who received all recommended PCV doses of <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>/<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>/<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> (according to either the routine or catch-up schedule) before age 6 years, the need for additional pneumococcal vaccination depends on the nature of the high-risk condition and whether they received at least one prior dose of PCV20:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-risk children who are immune-competent  (<a class="graphic graphic_table graphicRef68655" href="/z/d/graphic/68655.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the child received at least one prior dose of <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>, no additional doses of any pneumococcal vaccine are indicated.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the child did not previously receive a dose of <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>, administer either one dose of PCV20 or <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> to complete the vaccine series.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-risk children with immunocompromising conditions  (<a class="graphic graphic_table graphicRef68655" href="/z/d/graphic/68655.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the child received at least one prior dose of <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>, no additional doses of any pneumococcal vaccine are necessary.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the child did not previously receive a dose of <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>, administer either one dose of PCV20 or a dose of <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> at least eight weeks after the most recent PCV dose. If PPSV23 is given, then administer another PPSV23 dose or PCV20 at least five years after the first PPSV23 [<a href="#rid21">21</a>]. The second dose of PPSV23 is generally given five years after the first [<a href="#rid6">6,100,102</a>]; however, some experts recommend an interval of three years for children with sickle cell disease [<a href="#rid110">110</a>]. When PPSV23 is given, the ACIP recommends a total of two doses for immunocompromised children, including children with asplenia [<a href="#rid6">6,100</a>]; however, some experts suggest that children with asplenia receive PPSV23 every five years. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ages 6 through 18 years with</strong> <strong>incomplete recommended PCV series</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer one dose of <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> at least eight weeks after the most recent PCV. We prefer PCV20 when available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> vaccine is administered, administer a dose of <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> at least eight weeks later.</p><p></p><p class="headingAnchor" id="H1001166913"><span class="h2">Effectiveness</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunogenicity </strong>– Successful vaccination is indicated by a ≥2-fold increase in antigen-specific antibody between 4 and 12 weeks after immunization. The response for individual serotypes may vary. (See  <a class="medical medical_review" href="/z/d/html/3929.html" rel="external">"Assessing antibody function as part of an immunologic evaluation", section on 'Timing of pre- and postvaccination measurements'</a>.)</p><p></p><p class="bulletIndent1">There are few data regarding the immunogenicity of PPSVs in children belonging to high-risk groups. In observational studies, PPSVs have demonstrated immunogenicity in children with chronic renal disease, sickle cell disease, and HIV infection [<a href="#rid111">111-116</a>]. The duration of immunity following PCV is unknown [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Long-term follow-up data concerning antibody levels in people who received ≥2 doses of <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> are not available [<a href="#rid6">6</a>]. For people who have received two doses of PPSV23 at appropriate intervals, routine revaccination generally is not recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of IPD</strong> – The efficacy of PCV, PPSV, and the combination of PCV and PPSV in children at increased risk for IPD is not well studied [<a href="#rid117">117</a>]. Evidence from randomized and observational studies suggests that PCV prevents IPD in children with HIV infection and sickle cell disease [<a href="#rid36">36,118-120</a>]. In a randomized trial, the efficacy of PCV in preventing IPD in children with HIV was 65 percent (95% CI 24-86 percent) [<a href="#rid120">120</a>]. In a population-based observational study, the estimated effectiveness of ≥1 dose of PCV in preventing IPD among children ≤10 years with sickle cell disease was approximately 85 percent [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1">In an observational study, the estimated effectiveness of PPSV in preventing meningitis and bacteremia caused by vaccine serotypes in people ≥5 years of age was 57 percent (95% CI 45-66 percent) [<a href="#rid121">121</a>]. In another observational study, the estimated effectiveness of <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> in preventing IPD caused by vaccine serotypes in children two to five years of age with chronic disease was 63 percent (95% CI 8-85 percent) [<a href="#rid122">122</a>]. The effectiveness against the 16 serotypes included in the PPSV23 but not in PCV7 was 94 percent.</p><p></p><p class="bulletIndent1">The effectiveness of PPSV in preventing IPD in adults is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p></p><p class="headingAnchor" id="H866266433"><span class="h1">ADMINISTRATION OF PCV13/PCV15/PCV20 AND PPSV23</span></p><p class="headingAnchor" id="H2846822570"><span class="h2">Contraindications and precautions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications </strong>– The 13-valent (<a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>), the 15-valent (<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>), and the 20-valent pneumococcal conjugate vaccines (<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>) are contraindicated in children who had a severe allergic reaction (eg, anaphylaxis) after a previous dose of any PCV, any diphtheria toxoid-containing vaccine, or to a component of PCV13/PCV15/PCV20 or any diphtheria toxoid-containing vaccine [<a href="#rid3">3,4,6,123</a>]. (See  <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">"Allergic reactions to vaccines", section on 'Reactions to vaccine constituents'</a>.)</p><p></p><p class="bulletIndent1">The 23-valent <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">pneumococcal polysaccharide vaccine</a> (PPSV23) is contraindicated in children who had a severe allergic reaction to a previous dose or to a component of PPSV23 [<a href="#rid6">6,123</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Precautions are conditions that may increase the risk for a serious reaction to immunization, cause diagnostic confusion, or compromise the ability of the vaccine to produce immunity [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent1">Moderate or severe illness with or without fever is a precaution for administration of <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>/<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>/<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> and <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a>; postponing immunization until the child has recovered will avoid diagnostic confusion between manifestations of illness and vaccine adverse effects [<a href="#rid6">6,123</a>].</p><p></p><p class="headingAnchor" id="H1673376703"><span class="h2">Dose and route</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>, <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>, and <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> are administered intramuscularly (IM) as a single 0.5 mL dose [<a href="#rid6">6</a>]. <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> is administered IM or subcutaneously as a single 0.5 mL dose.</p><p class="headingAnchor" id="H3462051847"><span class="h2">Timing of vaccination</span><span class="headingEndMark"> — </span>If possible, pneumococcal immunization (<a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> and <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>, <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>, or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>) should be completed at least two weeks before splenectomy, immunocompromising therapy (including chemotherapy), or cochlear implantation [<a href="#rid6">6,109,124,125</a>]. Additional details regarding immunization of children undergoing splenectomy or cochlear implantation are provided separately. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'</a> and  <a class="medical medical_review" href="/z/d/html/5534.html" rel="external">"Cochlear implant infections", section on 'Children'</a>.)</p><p class="headingAnchor" id="H1682248311"><span class="h2">Administration with other vaccines</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a><strong>/</strong><a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a><strong>/</strong><a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Routine childhood vaccines</strong> – <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>, <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>, and <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> may be administered concurrently with other <strong>routine</strong> childhood vaccines [<a href="#rid8">8,10,12,89,92,126-130</a>]; PCV should be injected with a separate syringe at a separate site (eg, in a different limb [preferred] or separated by at least 2.5 cm [1 inch]) [<a href="#rid131">131</a>].</p><p></p><p class="bulletIndent2">To decrease immunization-related pain, we suggest administering oral rotavirus vaccine (if indicated) before injectable vaccines and administering PCV after other injectable vaccines. (See  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Administration of multiple vaccines at one visit'</a>.)</p><p></p><p class="bulletIndent1">In a randomized trial, the proportion of children who developed fever within two days of vaccination was similar (8 to 9 percent) whether <a class="drug drug_pediatric" data-topicid="12940" href="/z/d/drug information/12940.html" rel="external">inactivated influenza vaccine</a> was administered on the same day as PCV and diphtheria, tetanus, and acellular pertussis vaccine or two weeks later [<a href="#rid132">132</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vaccines for high-risk children</strong> – <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>, <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>, and <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> may be administered concurrently with most vaccines recommended for high-risk children [<a href="#rid8">8,131</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> – PPSV23 may be administered concurrently with other vaccines, but <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>, <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>, or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> [<a href="#rid131">131</a>]. In children ≥2 years of age and adolescents, PPSV23 should be administered ≥8 weeks before or after PCV13, PCV15, or PCV20.</p><p></p><p class="headingAnchor" id="H2429217701"><span class="h2">Adverse effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a><strong>, </strong><a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a><strong>, </strong><a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> – PCVs are generally safe and well tolerated [<a href="#rid8">8,20,133-135</a>]. In a systematic review of nine randomized trials including &gt;77,000 children, the most frequently reported adverse effects following PCV were mild local reactions, including localized pain and or tenderness (3 to 38 percent), erythema &lt;2.5 cm (5 to 20 percent) and swelling &lt;2.5 cm (5 to 12 percent), and fever &lt;39°C (102.2°F) (15 to 44 percent) [<a href="#rid135">135</a>]. More severe erythema, swelling, or fever were reported in &lt;2.5 percent of patients. Serious adverse events causally related to PCV were rare and did not differ between PCV and control groups. In randomized trials, the rate of adverse effects with PCV13 and PCV15 were similar between groups; adverse effects were typically mild and included fussiness, somnolence, injection site pain, and decreased appetite [<a href="#rid10">10,12,136,137</a>].</p><p></p><p class="bulletIndent1">Surveillance for prespecified adverse events in a cohort of children (one month to two years of age) who received nearly 600,000 doses of <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a> during the first two years after licensure (2010 to 2012) found no increased risk of febrile seizures, urticaria, angioneurotic edema, anaphylaxis, asthma, thrombocytopenia, or encephalopathy compared with PCV7 [<a href="#rid138">138</a>]. Although a potential association between PCV13 and Kawasaki disease was identified, no evidence of an association was detected when surveillance was continued through 2017 to include &gt;2.5 million doses nor in separate surveillance of &gt;6 million doses in the Sentinel Postlicensure Rapid Immunization Safety Monitoring (PRISM) surveillance system [<a href="#rid139">139,140</a>].</p><p></p><p class="bulletIndent1">Review of reports to the passive Vaccine Adverse Event Reporting System (VAERS) in the United States for children 6 weeks through 59 months of age between 2010 and 2017 did not identify any new or unexpected patterns of adverse reactions [<a href="#rid141">141</a>]. Reported adverse events were similar to those in prelicensure trials (eg, injection site erythema, injections site swelling, fever).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> – Approximately one-third to one-half of people who receive PPSV develop transient mild injection reactions (pain, erythema, swelling) [<a href="#rid117">117,142,143</a>]. These reactions usually persist for less than 48 hours. Moderate systemic reactions (eg, fever and myalgias) and more severe local reactions (eg, local induration) are rare. Revaccination after intervals of four years or more is not associated with an increased incidence of adverse side effects.</p><p></p><p>Health care providers in the United States should report suspected adverse events to <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Findex.html&amp;token=8m3rK0tzv73hmwLVujPJP%2FVrZTr5LmKIlDf%2BMKp07YKCkZawMmw76Mlq0N%2Fh3R%2BM&amp;TOPIC_ID=6053" target="_blank">VAERS</a>.</p><p class="headingAnchor" id="H3808023186"><span class="h1">SPECIAL CIRCUMSTANCES</span></p><p class="headingAnchor" id="H1615172227"><span class="h2">Uncertain immunization history</span><span class="headingEndMark"> — </span>Children with unknown or uncertain pneumococcal immunization status should be considered unimmunized [<a href="#rid131">131</a>]. They should be caught up according to age and risk status. (See <a class="local">'Schedule and catch-up schedule'</a> above and <a class="local">'Immunization of high-risk children and adolescents'</a> above.)</p><p class="headingAnchor" id="H4092327406"><span class="h2">Invasive pneumococcal disease</span><span class="headingEndMark"> — </span>Children who develop invasive pneumococcal disease (IPD) should still complete the full series of immunization with pneumococcal conjugate vaccine (<a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">13-valent pneumococcal conjugate vaccine</a> [PCV13], <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">15-valent pneumococcal conjugate vaccine</a> [PCV15], or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">20-valent pneumococcal conjugate vaccine</a> [PCV20]) and/or 23-valent <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">pneumococcal polysaccharide vaccine</a> (PPSV23) according to their age and underlying condition [<a href="#rid20">20</a>]. IPD elicits serotype-specific antibodies; it does not provide protection against the range of serotypes included in PCV13/PCV15 or PPSV23. Although the ACIP does not include severe IPD (eg, pneumococcal meningitis with sequelae, pneumococcal pneumonia with empyema or other complication) as a high-risk condition, some experts suggest that children with a history of severe IPD receive PPSV23 after completion of immunization with PCV13/PCV15. (See <a class="local">'Routine immunization for children &lt;5 years'</a> above and <a class="local">'Immunization of high-risk children and adolescents'</a> above.)</p><p>Evaluation of immune function and HIV status may be warranted for children who develop IPD disease with a <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>/<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> serotype despite having received at least two doses of PCV13/PCV15 [<a href="#rid125">125</a>]. However, in a multicenter study, immunodeficiency was detected in only 1 of 28 children who were evaluated for immunodeficiency after developing IPD with a PCV13 serotype despite having received ≥2 doses of PCV13 [<a href="#rid56">56</a>]. Additional studies are needed to clarify the need for evaluation of immune function in children who develop IPD with a PCV13/PCV15 serotype despite PCV13/PCV15 immunization.</p><p>Evaluation of immune function also may be warranted for select children who develop IPD with nonvaccine serotypes. In populations with high pneumococcal vaccine coverage, identification of primary immunodeficiency may be more likely in children with recurrent IPD and in children &gt;2 years of age who develop IPD with a nonvaccine serotype and have no other risk factors for IPD  (<a class="graphic graphic_table graphicRef68655" href="/z/d/graphic/68655.html" rel="external">table 3</a>) than in children who develop IPD despite PCV immunization [<a href="#rid101">101,105,144,145</a>]. In a systematic review of 17 predominantly retrospective studies including 6022 patients with IPD, primary immunodeficiency was identified in 11 to 67 percent of children with recurrent IPD, as many as 10.4 percent of children of all ages, and as many as 26 percent of children &gt;2 years [<a href="#rid105">105</a>]. Primary immunodeficiencies included immunoglobulin deficiency, pneumococcal antibody deficiency, complement deficiency, asplenia/hyposplenia, and defects in toll-like receptor signalling. Additional prospective studies are needed to clarify the need for evaluation of immune function.</p><p class="headingAnchor" id="H355932534"><span class="h2">Vaccine mix-up</span></p><p class="bulletIndent1"><span class="glyph">●</span>If a child &lt;2 years of age inadvertently receives <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> instead of <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>/<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>/<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>, the dose of PPSV23 should not be counted [<a href="#rid146">146</a>]. The child should receive PCV13/PCV15/PCV20 as soon as possible after the mix-up is recognized.</p><p></p><p class="bulletIndent1">Polysaccharide vaccines generally are not immunogenic in children &lt;2 years of age. Although children &lt;2 years of age may respond to some of the antigens in <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a>, the duration of response and effect on subsequent challenge are uncertain [<a href="#rid147">147-150</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a child ≥2 years of age inadvertently receives <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>/<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> instead of <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> (and did not require PCV13/PCV15), PPSV23 should be administered ≥8 weeks after the inadvertent dose of PCV13/PCV15.</p><p></p><p class="headingAnchor" id="H3727779961"><span class="h1">RESOURCES</span><span class="headingEndMark"> — </span>Resources related to pneumococcal immunization in children and adolescents include:</p><p class="bulletIndent1"><span class="glyph">●</span>Vaccine information statement for the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fpcv.html&amp;token=hDmNLVNz9JCOxlW1h%2FSU1g0DPeH9kMDYPbHwgO5KLZLOnAOpU1i5AYHCMzt3GSZ5H%2BASnmSnu2IDgBiEyaol7A%3D%3D&amp;TOPIC_ID=6053" target="_blank">pneumococcal conjugate vaccine (PCV13 or PCV15)</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fppv.html&amp;token=Jo%2BTJVXtdtuhdib4J4tH072hip9epmy%2BDF%2B2Em0MC%2BxGeZeKLyNvr%2F8mV8R3qQ6vsV3IddK1QEQ63uoGEqMKYA%3D%3D&amp;TOPIC_ID=6053" target="_blank">23-valent pneumococcal polysaccharide vaccine</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLMlA2kPbc%2FqiOcC%2F32sLF4g1y%2BAHPIpB3%2FyasJ9MUj3%2F&amp;TOPIC_ID=6053" target="_blank">The Centers for Disease Control and Prevention</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww2a.cdc.gov%2Fvaccines%2Fm%2Fpneumo%2Fpneumo.html&amp;token=N8qVJSrBCrbuXuD7GKvcN%2BGkwQLQ7IKRD0WskUEB1oAU%2F3x%2FQKivGUThAjjVztADglJJfWzbGBaZOZmHWPdaEw%3D%3D&amp;TOPIC_ID=6053" target="_blank">Pneumococcal vaccine recommendations advisor tool</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Facip-recs%2Fvacc-specific%2Fpneumo.html&amp;token=WjGfZKi63k46mWonwk%2B28QV4zjHCvMmYrY7bjJzfeT%2BrZIAHbZeAPS9wTrb%2FwfcgdwuQYjta10zHNMIYTzreExmrmSzyqGldLtMq3VzYNg8%3D&amp;TOPIC_ID=6053" target="_blank">The Advisory Committee on Immunization Practices recommendations for pneumococcal vaccine</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpatient-care%2Fimmunizations%2F&amp;token=IQxLzDq4doJGUgaZgeIY01qsm8D6OPt1e2CZs7qNDD9Vki1c5XPFvhIarxbXlaH%2FgCiVnpr391CqcLRvxCctPg%3D%3D&amp;TOPIC_ID=6053" target="_blank">The American Academy of Pediatrics</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLoejSdbdtDpI4EQKn%2BtqVzWf7RcpJipfWejk%2Bgy%2BCZPR%2F&amp;TOPIC_ID=6053" target="_blank">Immunize.org</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fimmunization-vaccines-and-biologicals%2Fpolicies%2Fposition-papers%2Fpneumococcus&amp;token=0E4l1wRCuGzOhDxn1GAC36NX9GHBO7uNziP6RQ8zgXBmTdsKEopO8iZ0WK5ZmYAinbZByW7Tcn%2Fr74Mk9kaJk7amjLSJGteW%2BL7wDtYmeOV4mxEyOZU8fkAdW9FPC0YB&amp;TOPIC_ID=6053" target="_blank">The World Health Organization</a></p><p></p><p class="headingAnchor" id="H3394766633"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109228.html" rel="external">"Society guideline links: Immunizations in children and adolescents"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110424.html" rel="external">"Society guideline links: Pneumococcal vaccination in children"</a>.)</p><p class="headingAnchor" id="H4224685921"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15370.html" rel="external">"Patient education: What you should know about vaccines (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15741.html" rel="external">"Patient education: Vaccines for babies and children age 0 to 6 years (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15742.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1214.html" rel="external">"Patient education: Why does my child need vaccines? (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1216.html" rel="external">"Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1218.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1200442555"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of pneumococcal vaccines</strong> – Two types of vaccines are available for the prevention of pneumococcal disease: pneumococcal polysaccharide-conjugate vaccines (usually called pneumococcal conjugate vaccines [PCV]) and pneumococcal polysaccharide vaccines (PPSV)  (<a class="graphic graphic_table graphicRef71746" href="/z/d/graphic/71746.html" rel="external">table 1</a>). (See <a class="local">'Pneumococcal vaccines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine immunization –</strong> In agreement with the World Health Organization and the United States Advisory Committee on Immunization Practices (ACIP), we recommend immunization with PCVs for all infants (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Children &lt;5 years of age, particularly those &lt;2 years of age, are at increased risk for invasive pneumococcal disease (IPD). Routine immunization with PCV is effective in preventing IPD in vaccinated children and providing community ("herd") immunity for unvaccinated people. The efficacy of PCV for preventing IPD is supported by several large randomized trials. Additional support comes from surveillance data demonstrating dramatic declines in the incidence of IPD after routine infant immunization was introduced. (See <a class="local">'Routine immunization for children &lt;5 years'</a> above and <a class="local">'Efficacy and effectiveness'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Schedule in the United States</strong> – In the United States, ACIP recommends routine immunization with either the 15-valent PCV (<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>) or the 20-valent PCV (<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>). When available, we suggest PCV20 rather than PCV15 (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). PCV is administered intramuscularly; the dose is 0.5 mL. The schedule for routine vaccination is as follows (see <a class="local">'Schedule and catch-up schedule'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age 2 months (minimum age 6 weeks)</p><p class="bulletIndent3"><span class="glyph">-</span>Age 4 months and ≥4 weeks after the first dose</p><p class="bulletIndent3"><span class="glyph">-</span>Age 6 months and ≥4 weeks after the second dose</p><p class="bulletIndent3"><span class="glyph">-</span>Booster dose at age 12 through 15 months and ≥8 weeks after the third dose</p><p></p><p class="bulletIndent2">If the infant received <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a> for the initial doses, the series may be completed with <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>. Restarting the series is not necessary.</p><p></p><p class="bulletIndent2">Healthy children between 2 and &lt;5 years of age who are incompletely immunized with PCV should receive a single dose of either <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> given at least eight weeks after the previous PCV dose (if applicable). (See <a class="local">'In the United States'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Schedules in other countries</strong> – The recommended schedules for European countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaccine-schedule.ecdc.europa.eu%2F&amp;token=hAC5nrgJRAh83rPs4U2YNoCvbRcaKCDdFzcO5xBYnRCBx4Y4AiuicnfZL3B%2BmfLV&amp;TOPIC_ID=6053" target="_blank">European Centre for Disease Prevention and Control</a>. (See <a class="local">'In other countries'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunization for high-risk children and adolescents</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Target high risk groups</strong> – The risk of IPD is increased in children ≥2 years of age who are immunocompromised or have a cerebrospinal fluid leak, cochlear implant, or certain medical conditions  (<a class="graphic graphic_table graphicRef68655" href="/z/d/graphic/68655.html" rel="external">table 3</a>). The risk is particularly high in children with sickle cell disease. (See <a class="local">'Target high-risk groups'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Approach to immunization</strong> – For children ≥2 years with high-risk conditions  (<a class="graphic graphic_table graphicRef68655" href="/z/d/graphic/68655.html" rel="external">table 3</a>) who have completed the primary vaccination series with <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>/<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a> and have not yet received a dose of <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>, we suggest immunization with PCV20 or <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> provides protection against serotypes that are not included in <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>, <a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>, or <a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>  (<a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">table 2</a>), but its efficacy is limited to children older than 2 years. (See <a class="local">'Aged-based immunization recommendations'</a> above.)</p><p></p><p class="bulletIndent2">The recommended schedule for <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">PCV13</a>/<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>/<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a> and <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">PPSV23</a> in high-risk children varies with age and pneumococcal vaccination history:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age &lt;2 years – Administer PCV according to the schedule for healthy children (see <a class="local">'Schedule and catch-up schedule'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age 2 through 18 years  (<a class="graphic graphic_algorithm graphicRef119302" href="/z/d/graphic/119302.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef119305" href="/z/d/graphic/119305.html" rel="external">algorithm 2</a>) (see <a class="local">'Age 2 through 18 years'</a> above)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Geno KA, Gilbert GL, Song JY, et al. Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev 2015; 28:871.</a></li><li class="breakAll">International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health. Gap analysis of PCV impact evaluations in settings of routine use. February 2017. Available at: https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html (Accessed on March 16, 2018).</li><li class="breakAll">Vaxneuvance (pneumococcal 15-valent conjugate vaccine) [package insert]. Whitehouse Station, NJ: Merck &amp; Co; 2021 https://www.fda.gov/media/150819/download (Accessed on September 19, 2022).</li><li class="breakAll">Prevnar 13. United States Prescribing Information. US Food &amp; Drug Administration. Revised August 2017. Available at: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm (Accessed on March 16, 2018).</li><li class="breakAll">Prevnar 20  (pneumococcal 20-valent conjugate vaccine ([package insert]. Philadelphia, PA: Pfizer; 2021. https://www.fda.gov/media/149987/download (Accessed on June 09, 2021).</li><li><a class="nounderline abstract_t">Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.</a></li><li><a class="nounderline abstract_t">Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:109.</a></li><li><a class="nounderline abstract_t">Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1174.</a></li><li><a class="nounderline abstract_t">Platt HL, Greenberg D, Tapiero B, et al. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J 2020; 39:763.</a></li><li class="breakAll">ClinicalTrials.gov. Safety, tolerability, and immunogenicity of V114 in healthy infants (V114-029) (PNEU-PED). Available at: https://clinicaltrials.gov/ct2/show/NCT03893448 (Accessed on September 19, 2022).</li><li class="breakAll">ClinicalTrials.gov. Safety and immunogenicity of catch-up vaccination regimens of V114 (V114–024) (PNEU-PLAN). Available at: https://ClinicalTrials.gov/show/NCT03885934 (Accessed on September 19, 2022).</li><li class="breakAll">ClinicalTrials.ogov. A study to evaluate the interchangeability of V114 and Prevnar 13 in healthy infants (V114–027/PNEUDIRECTION). Available at: https://ClinicalTrials.gov/show/NCT03620162 (Accessed on September 19, 2022).</li><li class="breakAll">ClinicalTrials.gov. A study to evaluate the safety, tolerability, and immunogenicity of V114 in children with sickle cell disease (V114–023/PNEU-SICKLE). Available at: https://ClinicalTrials.gov/show/NCT03731182 (Accessed on September 20, 2022).</li><li class="breakAll">ClinicalTrials.gov. Safety and immunogenicity of V114 in children infected with human immunodeficiency virus (HIV)
(V114–030/PNEU-WAY PED). Available at: https://clinicaltrials.gov/ct2/show/NCT03921424 (Accessed on September 20, 2022).</li><li class="breakAll">Prevnar 20. US Food and Drug Administration. Available at: https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20.</li><li><a class="nounderline abstract_t">Senders S, Klein NP, Lamberth E, et al. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr Infect Dis J 2021; 40:944.</a></li><li class="breakAll">Pneumovax 23 (pneumococcal vaccine polyvalent). US Food &amp; Drug Administration approved product information. Revised October 2011. US Food &amp; Drug Administration. Available at: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm (Accessed on August 22, 2018).</li><li><a class="nounderline abstract_t">Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39:930.</a></li><li><a class="nounderline abstract_t">Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983; 148:131.</a></li><li class="breakAll">World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. https://www.who.int/immunization/policy/position_papers/pneumococcus/en/ (Accessed on September 08, 2020).</li><li><a class="nounderline abstract_t">ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:1072.</a></li><li><a class="nounderline abstract_t">Rückinger S, van der Linden M, von Kries R. Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants. BMC Infect Dis 2010; 10:12.</a></li><li><a class="nounderline abstract_t">D'Angio CT, Heyne RJ, O'Shea TM, et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr Infect Dis J 2010; 29:600.</a></li><li><a class="nounderline abstract_t">Martinón-Torres F, Czajka H, Center KJ, et al. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics 2015; 135:e876.</a></li><li><a class="nounderline abstract_t">Martinón-Torres F, Wysocki J, Center KJ, et al. Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants. Pediatr Infect Dis J 2017; 36:326.</a></li><li><a class="nounderline abstract_t">Whitney CG. Examining Duration of Protection: Should a Booster Dose Be Part of All Infant Pneumococcal Conjugate Vaccine Programs? Clin Infect Dis 2018; 67:375.</a></li><li><a class="nounderline abstract_t">Zimmermann P, Perrett KP, Berbers G, Curtis N. Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine. Arch Dis Child 2019; 104:680.</a></li><li><a class="nounderline abstract_t">Jayasinghe S, Chiu C, Quinn H, et al. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study. Clin Infect Dis 2018; 67:367.</a></li><li class="breakAll">World Health Organization. Strategic Advisory Group of Experts (SAGE). Executive Summary SAGE October 2017, Pneumococcal Conjugate Vaccine Session. Available at: http://www.who.int/immunization/sage/meetings/2017/october/presentations_background_docs/en/ (Accessed on August 23, 2018).</li><li><a class="nounderline abstract_t">O'Brien KL. Optimizing the use of pneumococcal conjugate vaccine globally. JAMA 2013; 310:911.</a></li><li><a class="nounderline abstract_t">Blyth CC, Jayasinghe S, Andrews RM. A Rationale for Change: An Increase in Invasive Pneumococcal Disease in Fully Vaccinated Children. Clin Infect Dis 2020; 70:680.</a></li><li><a class="nounderline abstract_t">Adebanjo TA, Pondo T, Yankey D, et al. Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Zhu F, Hu Y, Li J, et al. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China. Pediatr Infect Dis J 2019; 38:1150.</a></li><li><a class="nounderline abstract_t">Lewnard JA, Givon-Lavi N, Dagan R. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children. Clin Infect Dis 2020; 71:e289.</a></li><li><a class="nounderline abstract_t">Deloria Knoll M, Park DE, Johnson TS, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J 2014; 33 Suppl 2:S119.</a></li><li><a class="nounderline abstract_t">Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009; :CD004977.</a></li><li><a class="nounderline abstract_t">Berman-Rosa M, O'Donnell S, Barker M, Quach C. Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease. Pediatrics 2020; 145.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Pneumococcal disease surveillance and reporting. Trends in invasive pneumococcal disease among children aged &lt;5 years old, 1998-2019. Available at: https://www.cdc.gov/pneumococcal/surveillance.html (Accessed on September 20, 2022).</li><li><a class="nounderline abstract_t">Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014; 59:1066.</a></li><li><a class="nounderline abstract_t">Moore CE, Paul J, Foster D, et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis 2014; 210:1001.</a></li><li><a class="nounderline abstract_t">Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15:535.</a></li><li><a class="nounderline abstract_t">Makwana A, Sheppard C, Borrow R, et al. Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010-2016. Pediatr Infect Dis J 2018; 37:697.</a></li><li><a class="nounderline abstract_t">Mackenzie GA, Hill PC, Jeffries DJ, et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. Lancet Infect Dis 2016; 16:703.</a></li><li><a class="nounderline abstract_t">Kellner JD, Vanderkooi OG, MacDonald J, et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49:205.</a></li><li><a class="nounderline abstract_t">von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014; 371:1889.</a></li><li><a class="nounderline abstract_t">van der Linden M, Falkenhorst G, Perniciaro S, et al. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany. PLoS One 2016; 11:e0161257.</a></li><li><a class="nounderline abstract_t">Glikman D, Dagan R, Barkai G, et al. Dynamics of Severe and Non-severe Invasive Pneumococcal Disease in Young Children in Israel Following PCV7/PCV13 Introduction. Pediatr Infect Dis J 2018; 37:1048.</a></li><li><a class="nounderline abstract_t">Petousis-Harris H, Howe AS, Paynter J, et al. Pneumococcal Conjugate Vaccines Turning the Tide on Inequity: A Retrospective Cohort Study of New Zealand Children Born 2006-2015. Clin Infect Dis 2019; 68:818.</a></li><li><a class="nounderline abstract_t">Hammitt LL, Etyang AO, Morpeth SC, et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet 2019; 393:2146.</a></li><li><a class="nounderline abstract_t">Kent A, Makwana A, Sheppard CL, et al. Invasive Pneumococcal Disease in UK Children &lt;1 Year of Age in the Post-13-Valent Pneumococcal Conjugate Vaccine Era: What Are the Risks Now? Clin Infect Dis 2019; 69:84.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203.</a></li><li><a class="nounderline abstract_t">Esposito S, Principi N. Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children. J Immunol Res 2015; 2015:591580.</a></li><li><a class="nounderline abstract_t">Steens A, Winje BA, White RA, et al. Indirect Effects of Pneumococcal Childhood Vaccination in Individuals Treated With Immunosuppressive Drugs in Ambulatory Care: A Case-cohort Study. Clin Infect Dis 2019; 68:1367.</a></li><li><a class="nounderline abstract_t">Baxter R, Aukes L, Pelton SI, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use. J Pediatric Infect Dis Soc 2021; 10:141.</a></li><li><a class="nounderline abstract_t">Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children. Clin Infect Dis 2015; 61:767.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Barson WJ, Lin PL, et al. Invasive Pneumococcal Disease in Children's Hospitals: 2014-2017. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Murad Y, Hung TY, Sadarangani M, et al. Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance Network. Pediatr Infect Dis J 2022; 41:e166.</a></li><li><a class="nounderline abstract_t">Metcalf BJ, Chochua S, Walker H, et al. Invasive Pneumococcal Strain Distributions and Isolate Clusters Associated With Persons Experiencing Homelessness During 2018. Clin Infect Dis 2021; 72:e948.</a></li><li><a class="nounderline abstract_t">Ben-Shimol S, Regev-Yochay G, Givon-Lavi N, et al. Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance. Clin Infect Dis 2022; 74:1639.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Active bacterial core surveillance. Surveillance reports. Streptococcus pneumoniae. Available at: https://www.cdc.gov/abcs/reports-findings/surv-reports.html (Accessed on September 20, 2022).</li><li><a class="nounderline abstract_t">Grant LR, Slack MPE, Theilacker C, et al. Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination. Clin Infect Dis 2023; 76:e1062.</a></li><li class="breakAll">CDC Active Bacterial Core surveillance. Bact Facts Interactive. Estimated number of cases and deaths of invasive Streptococcus pneumoniae infections in the United States. Available at: https://www.cdc.gov/abcs/bact-facts-interactive-dashboard.html (Accessed on September 20, 2022).</li><li><a class="nounderline abstract_t">Asner SA, Agyeman PKA, Gradoux E, et al. Burden of Streptococcus pneumoniae Sepsis in Children After Introduction of Pneumococcal Conjugate Vaccines: A Prospective Population-based Cohort Study. Clin Infect Dis 2019; 69:1574.</a></li><li class="breakAll">CDC Active Bacterial Core surveillance. Streptococcus pneumoniae. Trends by serotype group, 1998-2016. https://www.cdc.gov/abcs/reports-findings/survreports/spneu-types.html (Accessed on September 20, 2022).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893.</a></li><li><a class="nounderline abstract_t">Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006; 295:1668.</a></li><li><a class="nounderline abstract_t">Ladhani SN, Andrews NJ, Waight P, et al. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales. Clin Infect Dis 2013; 56:633.</a></li><li><a class="nounderline abstract_t">Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32.</a></li><li><a class="nounderline abstract_t">Olarte L, Barson WJ, Bradley JS, et al. Invasive Pneumococcal Disease in Infants Aged 0-60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era. J Pediatric Infect Dis Soc 2018; 7:249.</a></li><li><a class="nounderline abstract_t">Ahmed SS, Pondo T, Xing W, et al. Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States. Clin Infect Dis 2020; 70:2484.</a></li><li><a class="nounderline abstract_t">Olarte L, Barson WJ, Barson RM, et al. Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era. Clin Infect Dis 2017; 64:1699.</a></li><li><a class="nounderline abstract_t">Angoulvant F, Levy C, Grimprel E, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis 2014; 58:918.</a></li><li><a class="nounderline abstract_t">Ben-Shimol S, Greenberg D, Hazan G, et al. Differential impact of pneumococcal conjugate vaccines on bacteremic pneumonia versus other invasive pneumococcal disease. Pediatr Infect Dis J 2015; 34:409.</a></li><li><a class="nounderline abstract_t">Fathima P, Blyth CC, Lehmann D, et al. The Impact of Pneumococcal Vaccination on Bacterial and Viral Pneumonia in Western Australian Children: Record Linkage Cohort Study of 469589 Births, 1996-2012. Clin Infect Dis 2018; 66:1075.</a></li><li><a class="nounderline abstract_t">Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369:1179.</a></li><li><a class="nounderline abstract_t">Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155.</a></li><li><a class="nounderline abstract_t">Luca DL, Kwong JC, Chu A, et al. Impact of Pneumococcal Vaccination on Pneumonia Hospitalizations and Related Costs in Ontario: A Population-Based Ecological Study. Clin Infect Dis 2018; 66:541.</a></li><li><a class="nounderline abstract_t">Ouldali N, Levy C, Minodier P, et al. Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children. JAMA Pediatr 2019; 173:362.</a></li><li><a class="nounderline abstract_t">Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835.</a></li><li><a class="nounderline abstract_t">Madhi SA, Klugman KP, Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811.</a></li><li><a class="nounderline abstract_t">Madhi SA, Ludewick H, Kuwanda L, et al. Pneumococcal coinfection with human metapneumovirus. J Infect Dis 2006; 193:1236.</a></li><li><a class="nounderline abstract_t">Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187.</a></li><li><a class="nounderline abstract_t">de Sévaux JL, Venekamp RP, Lutje V, et al. Pneumococcal conjugate vaccines for preventing acute otitis media in children. Cochrane Database Syst Rev 2020; 11:CD001480.</a></li><li><a class="nounderline abstract_t">Dagan R, Ben-Shimol S, Greenberg D, Givon-Lavi N. A Prospective, Population-based Study to Determine the Incidence and Bacteriology of Bacterial Conjunctivitis in Children &lt;2 Years of Age Following 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Sequential Implementation. Clin Infect Dis 2021; 72:1200.</a></li><li><a class="nounderline abstract_t">Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368:1495.</a></li><li><a class="nounderline abstract_t">Mahon BE, Hsu K, Karumuri S, et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 2006; 24:2514.</a></li><li><a class="nounderline abstract_t">Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25:3816.</a></li><li class="breakAll">World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series. No. 927. 2005.</li><li><a class="nounderline abstract_t">Bryant KA, Block SL, Baker SA, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010; 125:866.</a></li><li><a class="nounderline abstract_t">Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010; 17:1017.</a></li><li><a class="nounderline abstract_t">Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010; 126:e493.</a></li><li><a class="nounderline abstract_t">Vanderkooi OG, Scheifele DW, Girgenti D, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J 2012; 31:72.</a></li><li><a class="nounderline abstract_t">Quinn CT, Wiedmann RT, Jarovsky D, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study. Blood Adv 2023; 7:414.</a></li><li><a class="nounderline abstract_t">O'Brien KL, Moisi J, Moulton LH, et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis 2007; 196:104.</a></li><li><a class="nounderline abstract_t">Dagan R, Givon-Lavi N, Greenberg D, et al. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010; 201:1570.</a></li><li><a class="nounderline abstract_t">Rodenburg GD, van Gils EJ, Veenhoven RH, et al. Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae. J Pediatr 2011; 159:965.</a></li><li><a class="nounderline abstract_t">van den Biggelaar AH, Pomat WS, Phuanukoonnon S, et al. Effect of early carriage of Streptococcus pneumoniae on the development of pneumococcal protein-specific cellular immune responses in infancy. Pediatr Infect Dis J 2012; 31:243.</a></li><li><a class="nounderline abstract_t">Rodenburg GD, van Gils EJ, Veenhoven RH, et al. Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses. Vaccine 2010; 28:1391.</a></li><li><a class="nounderline abstract_t">Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J 2010; 29:756.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62:521.</a></li><li><a class="nounderline abstract_t">Yildirim I, Shea KM, Little BA, et al. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease. Pediatrics 2015; 135:495.</a></li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a class="nounderline abstract_t">Jayasinghe S, Liu B, Gidding H, et al. Long-term Vaccine Impact on Invasive Pneumococcal Disease Among Children With Significant Comorbidities in a Large Australian Birth Cohort. Pediatr Infect Dis J 2019; 38:967.</a></li><li><a class="nounderline abstract_t">Ladhani SN, Slack MP, Andrews NJ, et al. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis 2013; 19:61.</a></li><li><a class="nounderline abstract_t">Butters C, Phuong LK, Cole T, Gwee A. Prevalence of Immunodeficiency in Children With Invasive Pneumococcal Disease in the Pneumococcal Vaccine Era: A Systematic Review. JAMA Pediatr 2019; 173:1084.</a></li><li><a class="nounderline abstract_t">Wodi AP, Murthy N, McNally V, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:137.</a></li><li><a class="nounderline abstract_t">Simons M, Scott-Sheldon LAJ, Risech-Neyman Y, et al. Celiac Disease and Increased Risk of Pneumococcal Infection: A Systematic Review and Meta-Analysis. Am J Med 2018; 131:83.</a></li><li><a class="nounderline abstract_t">Garcia Garrido HM, Mak AMR, Wit FWNM, et al. Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting. Clin Infect Dis 2020; 71:41.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices. Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2003; 52:739.</a></li><li class="breakAll">National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease. Expert Panel Report, 2014. www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines (Accessed on June 12, 2015).</li><li><a class="nounderline abstract_t">Furth SL, Neu AM, Case B, et al. Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration. J Pediatr 1996; 128:99.</a></li><li><a class="nounderline abstract_t">Ammann AJ, Addiego J, Wara DW, et al. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med 1977; 297:897.</a></li><li><a class="nounderline abstract_t">Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920.</a></li><li><a class="nounderline abstract_t">De Montalembert M, Abboud MR, Fiquet A, et al. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. Pediatr Blood Cancer 2015; 62:1427.</a></li><li><a class="nounderline abstract_t">Madhi SA, Kuwanda L, Cutland C, et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005; 24:410.</a></li><li><a class="nounderline abstract_t">Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003; 112:66.</a></li><li><a class="nounderline abstract_t">23-valent pneumococcal   polysaccharide vaccine.   WHO position paper. Wkly Epidemiol Rec 2008; 83:373.</a></li><li><a class="nounderline abstract_t">Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1428.</a></li><li><a class="nounderline abstract_t">Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008; 121:562.</a></li><li><a class="nounderline abstract_t">Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341.</a></li><li><a class="nounderline abstract_t">Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826.</a></li><li><a class="nounderline abstract_t">Fiore AE, Levine OS, Elliott JA, et al. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. Emerg Infect Dis 1999; 5:828.</a></li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Contraindications and precautions. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html (Accessed on November 15, 2022).</li><li><a class="nounderline abstract_t">van Aalst M, Garcia Garrido HM, van der Leun J, et al. Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease. Clin Infect Dis 2020; 70:595.</a></li><li class="breakAll">American Academy of Pediatrics. Streptococcus pneumoniae (pneumococcal) infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.717.</li><li><a class="nounderline abstract_t">Gimenez-Sanchez F, Kieninger DM, Kueper K, et al. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine 2011; 29:6042.</a></li><li><a class="nounderline abstract_t">Leonardi M, Bromberg K, Baxter R, et al. Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. Pediatrics 2011; 128:e1387.</a></li><li><a class="nounderline abstract_t">Bryant KA, Gurtman A, Girgenti D, et al. Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:383.</a></li><li><a class="nounderline abstract_t">Togashi T, Okada K, Yamaji M, et al. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan. Pediatr Infect Dis J 2015; 34:1096.</a></li><li><a class="nounderline abstract_t">Gasparini R, Tregnaghi M, Keshavan P, et al. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J 2016; 35:81.</a></li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Vaccine Administration. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html (Accessed on September 20, 2022).</li><li><a class="nounderline abstract_t">Walter EB, Klein NP, Wodi AP, et al. Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Ruiz-Aragón J, Márquez Peláez S, Molina-Linde JM, Grande-Tejada AM. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis. Vaccine 2013; 31:5349.</a></li><li><a class="nounderline abstract_t">Thompson A, Gurtman A, Patterson S, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine 2013; 31:5289.</a></li><li><a class="nounderline abstract_t">Fortanier AC, Venekamp RP, Boonacker CW, et al. Pneumococcal conjugate vaccines for preventing acute otitis media in children. Cochrane Database Syst Rev 2019; 5:CD001480.</a></li><li class="breakAll">Merck Sharp &amp; Dohme LLC. Merck data on file, P027 clinical study report section 16.2.7.1.3: listing of participants with serious adverse events. Charlotte, NC: Merck Sharp &amp; Dohme LLC; 2021.</li><li class="breakAll">ClinicalTrials.gov. A study to evaluate the safety and tolerability of V114 and Prevnar 13 in healthy infants (V114–031/PNEU-LINK). Available at: https://ClinicalTrials.gov/show/NCT03692871 (Accessed on September 20, 2022).</li><li><a class="nounderline abstract_t">Tseng HF, Sy LS, Liu IL, et al. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine 2013; 31:2578.</a></li><li><a class="nounderline abstract_t">Kamidani S, Panagiotakopoulos L, Licata C, et al. Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Baker MA, Baer B, Kulldorff M, et al. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results. PLoS Med 2019; 16:e1002844.</a></li><li><a class="nounderline abstract_t">Arana J, Moro P, Lewis P, et al. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in children 6 weeks–59 months old, Vaccine Adverse Event Reporting System (VAERS), United States, 2010–2017. Open Forum Infect Dis 2017; 4:S464.</a></li><li><a class="nounderline abstract_t">Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154:2666.</a></li><li><a class="nounderline abstract_t">Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J Infect Dis 1984; 149:861.</a></li><li><a class="nounderline abstract_t">Pelton SI, Lapidot R, Yildirim I. Invasive Pneumococcal Disease-Not Evenly Shared by All Children. JAMA Pediatr 2019; 173:1023.</a></li><li><a class="nounderline abstract_t">Bijker EM, Bateman EAL, Trück J, et al. Screening for Immunodeficiencies in Children With Invasive Pneumococcal Disease: Six-year Experience From a UK Children's Hospital. Pediatr Infect Dis J 2022; 41:575.</a></li><li class="breakAll">Immunize.org. Ask the Experts. Pneumococcal vaccines (PCV13 and PPSV23). Available at: http://www.immunize.org/askexperts/experts_pneumococcal_vaccines.asp (Accessed on September 20, 2022).</li><li><a class="nounderline abstract_t">Pomat WS, Lehmann D, Sanders RC, et al. Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea. Infect Immun 1994; 62:1848.</a></li><li><a class="nounderline abstract_t">Peset Llopis MJ, Harms G, Hardonk MJ, Timens W. Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells. J Allergy Clin Immunol 1996; 97:1015.</a></li><li><a class="nounderline abstract_t">Sorensen RU, Leiva LE, Javier FC 3rd, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 1998; 102:215.</a></li><li><a class="nounderline abstract_t">Balloch A, Licciardi PV, Russell FM, et al. Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J Allergy Clin Immunol 2010; 126:395.</a></li></ol></div><div id="topicVersionRevision">Topic 6053 Version 113.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26085553" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pneumococcal Capsules and Their Types: Past, Present, and Future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26085553" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pneumococcal Capsules and Their Types: Past, Present, and Future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26085553" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pneumococcal Capsules and Their Types: Past, Present, and Future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26085553" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pneumococcal Capsules and Their Types: Past, Present, and Future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26085553" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pneumococcal Capsules and Their Types: Past, Present, and Future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150868" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35085226" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36107786" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639460" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639460" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639460" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639460" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639460" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639460" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639460" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34525007" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34525007" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472842" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6886479" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antibody response to pneumococcal vaccination in children younger than five years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6886479" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antibody response to pneumococcal vaccination in children younger than five years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37768876" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20085656" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20234331" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25780077" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27902652" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29471317" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Examining Duration of Protection: Should a Booster Dose Be Part of All Infant Pneumococcal Conjugate Vaccine Programs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30796020" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29471432" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29471432" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24002275" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Optimizing the use of pneumococcal conjugate vaccine globally.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31209491" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A Rationale for Change: An Increase in Invasive Pneumococcal Disease in Fully Vaccinated Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32054822" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31626050" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31784753" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24336054" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821336" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32156773" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32156773" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25034421" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719477" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801458" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889811" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26897105" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508165" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25386897" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effects of vaccination on invasive pneumococcal disease in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27526117" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29750768" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dynamics of Severe and Non-severe Invasive Pneumococcal Disease in Young Children in Israel Following PCV7/PCV13 Introduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30032236" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pneumococcal Conjugate Vaccines Turning the Tide on Inequity: A Retrospective Cohort Study of New Zealand Children Born 2006-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31000194" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30281069" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Invasive Pneumococcal Disease in UK Children&lt;1 Year of Age in the Post-13-Valent Pneumococcal Conjugate Vaccine Era: What Are the Risks Now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23558320" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26351648" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30957160" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Indirect Effects of Pneumococcal Childhood Vaccination in Individuals Treated With Immunosuppressive Drugs in Ambulatory Care: A Case-cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32415771" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972022" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31420369" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Invasive Pneumococcal Disease in Children's Hospitals: 2014-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35093996" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33150366" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Invasive Pneumococcal Strain Distributions and Isolate Clusters Associated With Persons Experiencing Homelessness During 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34293091" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34293091" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35789262" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35789262" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30601988" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Burden of Streptococcus pneumoniae Sepsis in Children After Introduction of Pneumococcal Conjugate Vaccines: A Prospective Population-based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30601988" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Burden of Streptococcus pneumoniae Sepsis in Children After Introduction of Pneumococcal Conjugate Vaccines: A Prospective Population-based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16163262" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16609088" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23175560" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19947881" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28510699" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Invasive Pneumococcal Disease in Infants Aged 0-60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31402387" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199482" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24532543" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25764098" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Differential impact of pneumococcal conjugate vaccines on bacteremic pneumonia versus other invasive pneumococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29069315" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The Impact of Pneumococcal Vaccination on Bacterial and Viral Pneumonia in Western Australian Children: Record Linkage Cohort Study of 469589 Births, 1996-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17416262" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23841730" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029063" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Impact of Pneumococcal Vaccination on Pneumonia Hospitalizations and Related Costs in Ontario: A Population-Based Ecological Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30715140" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25714161" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Community-acquired pneumonia requiring hospitalization among U.S. children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247911" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A role for Streptococcus pneumoniae in virus-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586360" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pneumococcal coinfection with human metapneumovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10749457" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33231293" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pneumococcal conjugate vaccines for preventing acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32140705" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A Prospective, Population-based Study to Determine the Incidence and Bacteriology of Bacterial Conjunctivitis in Children&lt;2 Years of Age Following 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Sequential Implementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17071283" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16417951" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17368878" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17368878" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20435707" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427630" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20732948" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21960186" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36383730" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538890" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20384496" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813135" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22189528" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effect of early carriage of Streptococcus pneumoniae on the development of pneumococcal protein-specific cellular immune responses in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19931382" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20661103" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23803961" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25647674" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31408056" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Long-term Vaccine Impact on Invasive Pneumococcal Disease Among Children With Significant Comorbidities in a Large Australian Birth Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23259937" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566672" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Prevalence of Immunodeficiency in Children With Invasive Pneumococcal Disease in the Pneumococcal Vaccine Era: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36757872" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28801224" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Celiac Disease and Increased Risk of Pneumococcal Infection: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31634398" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12908457" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12908457" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8551427" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20575" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17006288" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25810327" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15876939" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12837869" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18927997" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : 23-valent pneumococcal   polysaccharide vaccine.   WHO position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17479937" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18310206" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523142" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8411526" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10603221" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10603221" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30899961" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30899961" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21704105" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123890" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23104129" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26121200" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398743" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398743" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32029684" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24055349" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23973321" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31135969" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Pneumococcal conjugate vaccines for preventing acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31135969" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Pneumococcal conjugate vaccines for preventing acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31135969" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Pneumococcal conjugate vaccines for preventing acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23579258" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36349537" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31265459" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in children 6 weeks–59 months old, Vaccine Adverse Event Reporting System (VAERS), United States, 2010–2017</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993150" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6376653" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566674" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Invasive Pneumococcal Disease-Not Evenly Shared by All Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35421038" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Screening for Immunodeficiencies in Children With Invasive Pneumococcal Disease: Six-year Experience From a UK Children's Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35421038" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Screening for Immunodeficiencies in Children With Invasive Pneumococcal Disease: Six-year Experience From a UK Children's Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8168948" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8655878" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9723664" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584544" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
